Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Inclusion and exclusion criteria for BED participants

From: Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol

Criteria List
Inclusion • Age 18–40 years.
• BED diagnosis, confirmed by the eating disorders module of the Structured Clinical Interview for DSM-5.
• Moderate to severe BED, defined as the presence of binge eating frequency of ≥3 days/week in the month prior to the baseline assessment and a score of ≥4 on the clinical global impressions severity scale.
• BMI of 20 – 45 kg/m2.
• A study doctor has verified that it is medically and psychiatrically safe for their patient to commence LDX.
• Fluent in English.
• Have provided written informed consent.
Exclusion • History of psychosis or mania.
• Pregnant or breast-feeding women.
• Current therapy with antipsychotics or noradrenaline reuptake inhibitors.
• Current therapeutic intervention specific to treating eating behaviours and/or cognitions.
• Cardiovascular disease, hypertension, use of monoamine oxidase inhibitors, or any other contraindications for psychostimulants.
• History of substance abuse/dependence (excluding nicotine).
• Previous suicide attempts or current suicidal ideation.
• Known medical condition, disease or neurological disorder which might, in the opinion of investigator/s, interfere with the assessments to be made in the study or put BED patients at increased risk when exposed to optimal doses of the drug treatment.
• Use of a psychostimulant in the 6 months prior to the study.
• Inability to tolerate the MRI scanner due to physical or psychological factors.
• History of physical brain injury or blow to the head that resulted in loss of consciousness for at least 10 min.